Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.3% – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares were down 3.3% during mid-day trading on Wednesday . The stock traded as low as $23.07 and last traded at $23.08. Approximately 17,679 shares traded hands during trading, a decline of 91% from the average daily volume of 205,885 shares. The stock had previously closed at $23.86.

Analysts Set New Price Targets

DNTH has been the topic of several recent analyst reports. Raymond James lifted their price target on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Wedbush decreased their price target on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. Oppenheimer lifted their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $46.43.

Dianthus Therapeutics Trading Down 0.1 %

The company’s 50-day moving average is $26.82 and its two-hundred day moving average is $26.59.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. On average, research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Large investors have recently bought and sold shares of the business. Quest Partners LLC boosted its holdings in shares of Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Dianthus Therapeutics in the second quarter worth approximately $112,000. The Manufacturers Life Insurance Company bought a new stake in Dianthus Therapeutics in the 2nd quarter worth approximately $236,000. Fred Alger Management LLC raised its stake in Dianthus Therapeutics by 52.5% during the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock valued at $264,000 after buying an additional 3,316 shares during the last quarter. Finally, WINTON GROUP Ltd bought a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at $265,000. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.